Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood–brain barrier

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Be´duneaua A, Saulniera P, Benoita J-P: Active targeting of brain tumors using nanocarriers. Biomaterials28,4947–4967 (2007).▪ Comprehensive review on the active targeting nanocarriers for the brain tumor treatment.
  MedlineGoogle Scholar
• 2  Gururangan S, Friedman HS: Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clin. N. Am.12(4),583–597 (2002).
  MedlineGoogle Scholar
• 3  Ehrlich P: Das Sauerstoffbedurfnis des Organismus: Ein Farbenanalytische Studie. Hirschwald A, Berlin (1885).
  Google Scholar
• 4  Ohnishi T, Tamai I, Sakanaka K et al.: In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood–brain barrier. Biochem. Pharmacol.49,1541–1544 (1995).
  Medline CASGoogle Scholar
• 5  Misra A, Ganesh S, Shahiwala A, Shah SP: Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci.6(2),252–273 (2003).
  Medline CASGoogle Scholar
• 6  Lockman PR, Mumper RJ, Khan M A, Allen DD: Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev. Ind. Pharm.28(1),1–12 (2002).
  Medline CASGoogle Scholar
• 7  Vinagradov SV, Bronich TK, Kabanov AV: Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Del. Rev.54,223–233 (2002).
  MedlineGoogle Scholar
• 8  Feng SS, Mu L, Win KY, Huang GF: Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem.11,413–424 (2004).
  Medline CASGoogle Scholar
• 9  Feng SS, Chien S: Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci.58,4087–4014 (2003).▪▪ Comprehensive introduction of chemotherapeutic engineering for developing new dosage forms of the drugs for chemotherapy of cancer and other diseases.
  CASGoogle Scholar
• 10  Pandey R, Khuller GK: Polymer based drug delivery systems for mycobacterial infections. Curr. Drug Deliv.1,195–201(2004).
  Medline CASGoogle Scholar
• 11  Ahlin P, Kristl L, Kristl A, Vrecer F: Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int. J. Pharm.239,113–120 (2002).
  Medline CASGoogle Scholar
• 12  Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR: Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci.92,1085–1094 (2003).
  Medline CASGoogle Scholar
• 13  Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK: Poly(DL-lactide-co-glycolide) nanoparticles based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother.52,981–986 (2003).
  Medline CASGoogle Scholar
• 14  Florence AT, Hillery AM, Hussain N, Jani PU: Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J. Control. Release36,39–46 (1995).
  CASGoogle Scholar
• 15  Garcia-Garcia E, Andrieux K, Gilb S, Couvreur P: Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm.298,274–292 (2005).
  Medline CASGoogle Scholar
• 16  Kaili Hu, Jingwei Li, Yehong Shen et al.: Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Control. Release134,55–61 (2009).
  MedlineGoogle Scholar
• 17  Barnabas W, Malay Kumar S, Kumaraswamy S, Kokilampal Perumal SK, Nallupillai P, Bhojraj S: Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Euro. J. Pharm. Biopharm.70,75–84 (2008).
  MedlineGoogle Scholar
• 18  Kreuter J: Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev.47,65–81 (2001).
  Medline CASGoogle Scholar
• 19  Calvo P, Gouritin B, Chacun H et al.: Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmacol. Res.18,1157–1166 (2001).
  CASGoogle Scholar
• 20  Steiniger SC, Kreuter J, Khalansky AS et al.: Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer109,759–767 (2004).
  Medline CASGoogle Scholar
• 21  Wang C-X, Huang L-S, Hou L-B et al.: Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res.1261,91–99 (2009).
  Medline CASGoogle Scholar
• 22  Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J: Influence of surfactants, polymer and doxorubicin loading on the anti-tumor effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J. Microencapsul.23,582–592 (2006).
  Medline CASGoogle Scholar
• 23  Petri B, Bootz A, Khalansky A et al.: Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release117,51–58 (2007).
  Medline CASGoogle Scholar
• 24  Gelperina S, Maksimenko O, Khalansky A et al.: Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Euro. J. Pharm. Biopharm.74(2),157–163(2010).▪ Presents the effect of formulation parameters of the surface-coated polymer nanoparticles on drug delivery to the brain.
  Medline CASGoogle Scholar
• 25  Kreuter J, Shamenkov D, Petrov V et al.: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J. Drug Target.10,317–325 (2002).▪ Presents the effect of surface-coated nanoparticles for brain drug-delivery applications.
  Medline CASGoogle Scholar
• 26  Gao K, Jiang X: Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm.310,213–219 (2006).
  Medline CASGoogle Scholar
• 27  Craparo EF, Ognibene MC, Casaletto MP et al.: Biocompatible polymeric micelles with polysorbate 80 for use in brain targeting. Nanotechnology19(48), Article Number: 485603 (2008).
  MedlineGoogle Scholar
• 28  Engels FK, Mathot RAA, Verweij J: Alternative drug formulations of docetaxel: a review. Anticancer Drugs18(2),95–103 (2007).
  Medline CASGoogle Scholar
• 29  Koziara JM, Lockman PR, Allen DD et al.: Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release99(2),259–269 (2004).
  Medline CASGoogle Scholar
• 30  Van Tellingen O, Beijnen JH, Verweij J et al.: Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res.5(10),2918–2924 (1999).
  Medline CASGoogle Scholar
• 31  Veronsi B: Characterization of the MDCK cell line for screening neurotoxicants. Neurotoxicology17,433–443 (1996).
  MedlineGoogle Scholar
• 32  Polli JW, Humphreys JE, Wring SA et al.: A comparison of Madin–Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery. In: Progress in the reduction, refinement and replacement of animal experimentation. Balls M, van Zeller AM, Halder ME (Eds). Elsevier Sciences, Amsterdam, Netherlands 271–289 (2000).
  Google Scholar
• 33  Lundquist S, Renftel M: The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood–brain barrier in the pharmaceutical industry-background and current status in the drug discovery process. Vascular Pharmacol.38,355–364 (2002)
  Medline CASGoogle Scholar
• 34  Cho MJ, Thompson DP, Cramer CT et al.: The madin darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm. Res.3,71–77 (1989).
  Google Scholar
• 35  Wang Q, Rager JD, Weinstein K et al.: Evaluation of the MDRMDCK cell line as a permeability screen for the blood–brain barrier. Int. J. Pharm.288,349–59 (2005).
  Medline CASGoogle Scholar
• 36  Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM: The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials30,2790–2798 (2009).
  Medline CASGoogle Scholar
• 37  Sun W, Xie C, Wang H, Hu Yu: Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials25,3065–3071 (2004).
  Medline CASGoogle Scholar
• 38  Davda J, Labhasetwar V: Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm.233,51–59 (2002).
  Medline CASGoogle Scholar
• 39  Sahoo SK, Panyam J, Prabha S, Labhasetwar V: Residual polyvinyl alcohol associated with poly (D,L-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release82,105–114 (2002).
  Medline CASGoogle Scholar
• 40  Panyam J, Zhou Wen-Zhong, Prabha S, Sahoo SK, Labhasetwar V: Rapid endo-lysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: implications for drug and gene delivery. The FASEB J.16,1217–1226 (2002).
  Medline CASGoogle Scholar
• 41  Shan N, Chaudhari K, Dantuluri P, Murthy RSR, Das S: Paclitaxel-loaded PLGA nanoparticles surface modified with transferring and Pluronic^® P85, an in vitro cell line and in vivo biodistibution studies on rat model. J. Drug Targeting17(7),533–543 (2009).
  MedlineGoogle Scholar
• 42  Wilson B, Samanta MK, Santhi K, Sampath Kumar KP, Paramakrishnan N, Suresh B: Targeted delivery of tacrine into the brain with polysorbate 80-coated poly (N-butylcynoacrlate) nanoparticles. Euro. J. Pharm. Biopharm.70,75–84 (2008).
  Medline CASGoogle Scholar
• 43  Mu L, Feng SS: Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxols). J. Control. Release80,129–44 (2002).
  Medline CASGoogle Scholar
• 44  Mu L, Feng SS: A novel controlled release formulation for anticancer drug paclitaxel (Taxols): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release86, (33–48) 2003.
  Medline CASGoogle Scholar
• 45  Mu L, Feng SS: PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and the drug loading ratio. Pharm. Res.20,1864–1872 (2003).
  Medline CASGoogle Scholar
• 46  Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL: The mechanism of uptake of biodegradable microparticles in caco-2 cells is size dependent. Pharm. Res14,1568–1573 (1997).
  Medline CASGoogle Scholar
• 47  Tabata Y, Ikada Y: Phagocytosis of polymeric microspheres by microphages. Adv. Polymer Sci.94,104–141 (1990).
  Google Scholar
• 48  Hillery AM, Florence AT: The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat. Int. J. Pharm.132,123–130 (1996).
  CASGoogle Scholar
• 49  Illum L, Davis SS: Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J. Pharm. Sci.72,1086–1088 (1983).
  Medline CASGoogle Scholar
• 50  Porter CJH, Moghimi SM, Illum L, Davis SS: The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett.305,62–66 (1992).
  Medline CASGoogle Scholar
• 51  Rutter PR, Vincent B: The adhesion of micro-organisms to surfaces: physicochemical aspects. In Microbial Adhesion to Surfaces. Berkeley RCW, Melling J, Rutter PR, Vincent B (Eds.) Ellis Horwood, Chichester UK, 79–91 (1980).
  Google Scholar
• 52  Silberberg A: The role of membrane-bound macromolecules and macromolecules in solutions in cell/cell encounters in flowing blood. Ann. New York Acad. Sci.416,83–91 (1984).
  Google Scholar
• 53  Tan JS, Butterfield DE, Voycheck CL, Caldwell KD, Li JT: Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood circulations in rats. Biomaterials14(11),823–833 (1993).
  Medline CASGoogle Scholar
• 54  Lo Y-L: Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release90,37–48 (2003).
  Medline CASGoogle Scholar
• 55  Wang J, Zhang Q: Uptake of cyclosporine a loaded colloidal drug carriers by mouse peritoneal microphages in vitro. Acta Phamacol. Sin.22(1),57–61 (2001).
  Medline CASGoogle Scholar
• 56  Batrakova EV, Kabanov AV: Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release130,98–106 (2008).
  Medline CASGoogle Scholar